7th Nov 2005 14:00
7 November 2005Shire Pharmaceuticals Group plc (the "Company")The Company announces that it was notified today, in accordance with Sections198 to 202 of the Companies Act, that as at 2 November 2005, Barclays PLC,through its associated companies, held a notifiable interest, in aggregate, of20,290,124 ordinary shares of ‚£0.05p each in the capital of the Company. Theseholdings represent 4.10 per cent of the issued ordinary share capital of theCompany.T MayCompany SecretaryFor further information please contact:Investor Relations Clƒ©a Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing and marketing products in the areas ofcentral nervous system (CNS), gastrointestinal (GI), general products and humangenetic therapies. Shire has operations in the world's key pharmaceuticalmarkets (US, Canada, UK, France, Italy, Spain and Germany) as well as aspecialist drug delivery unit in the US.For further information on Shire, please visit the Company's website: www.shire.com. Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDShire Pharmaceuticals Group PLCRelated Shares:
BarclaysShire